Rhizen Pharmaceuticals S.A. announces scientific presentations on the therapeutic potential of their lead dual PI3K delta/gamma inhibitor and CRAC channel inhibitor at the ERS Annual Conference at Barcelona, Spain, 7-11 September 2013
September 06, 2013 06:03 ET
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Sept. 6, 2013 (GLOBE NEWSWIRE) -- La Chaux-de-Fonds, Switzerland (6 September 2013): Rhizen
Pharmaceuticals S.A. announces a scientific poster presentation on
the...